logo-loader

Arecor Therapeutics, EMV Capital, Creo Medical, hVIVO, DigitalBox, Ilika - Small Cap Week in Review

Published: 03:30 27 Sep 2025 EDT

Arecor Therapeutics PLC (AIM:AREC) has teamed up with Sequel Med Tech to develop AT278, an ultra-concentrated insulin for pumps. Both firms are funding development, while a US$11 million royalty financing deal with Ligand Pharmaceuticals extends Arecor’s cash runway into 2027. Watch more

EMV Capital (AIM:EMVC) picked up assets from the collapsed Destiny Pharma, including phase 2 proven XF-73. The company aims to restart phase 3 trials, targeting the big US market for hospital infections with a low-cost model. Watch more

Creo Medical Group PLC (AIM:CREO, OTC:CMEOF) reported 40% revenue growth on stronger adoption of its Speedboat technology. A £25 million deal with Micro-Tech added cash, while SpydrBlade gained US clearance and new markets are opening up. Watch more

hVIVO PLC (AIM:HVO) booked £24 million in revenue, supported by a diversified mix of services, therapeutics and clients, and £3 million in EBITDA. It expects £47.00 million for the full year, with a return to growth forecast for 2026. Watch more

Digitalbox PLC (AIM:DBOX) saw page impressions rise 15% and reach up 30%, driving 12% revenue growth in the first half. On-platform revenue jumped to £400,000, while its social following soared to nearly 30 million. Watch more

Ilika PLC (AIM:IKA, OTCQX:ILIKF) launched its PRIMED programme to back solid-state battery development. Work with UK BIC and Jaguar Land Rover supports 50Ah A-Sample batteries and future large-scale production. Watch more

Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.

Poolbeg Pharma, Arecor Therapeutics, hVIVO, Ilika, Kodal Minerals,...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has cleared its final regulatory hurdle, with full MHRA approval secured for its TOPICAL trial across six UK sites. Interim data on its CRS therapy is expected this summer, with US payer research pointing to a big opportunity. Watch...

on 04/19/2026